Trial Profile
The Real World Evidence On Treatment Patterns, Effectiveness, And Safety Of Drugs For Stroke Prevention In Nonvalvular Atrial Fibrillation Patients In Korea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Antiplatelets (Primary) ; Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Stroke; Thromboembolism
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 May 2022 Results assessing drug utilization pattern of oral anticoagulants in patients with atrial fibrillation published in the Advances in Therapy
- 18 Nov 2019 Status changed from recruiting to completed.
- 22 May 2019 Status changed from active, no longer recruiting to recruiting.